sales@theinsightpartners.com
+1-646-491-9876 +44-20-8125-4005

Female Hypoactive Sexual Desire Disorder Therapeutics Market Scope And Analysis

  • Report Code : TIPRE00010487
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Análisis del alcance del informe de mercado de terapias para el trastorno del deseo sexual hipoactivo femenino y oportunidades para 2025-2031

Buy Now

Female Hypoactive Sexual Desire Disorder Therapeutics Market Report Female Hypoactive Sexual Desire Disorder Therapeutics Market Size and Share Female Hypoactive Sexual Desire Disorder Therapeutics Market Scope and Analysis

Female Hypoactive Sexual Desire Disorder Therapeutics Market Report Scope

Report Attribute Details
Market size in 2023 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2023 - 2031) XX%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Terapia
  • testosterona
  • flibanserina
  • buspirona
  • bupropión
  • bremelanotida
  • terapia cognitivo-conductual
By Solicitud
  • paciente hospitalizado
  • ambulatorio
By Geografía
  • América del Norte
  • Europa
  • Asia-Pacífico
  • América del Sur y Central
Regions and Countries Covered América del Norte
  • EE. UU.
  • Canadá
  • México
Europa
  • Reino Unido
  • Alemania
  • Francia
  • Rusia
  • Italia
  • resto de Europa
Asia-Pacífico
  • China
  • India
  • Japón
  • Australia
  • resto de Asia-Pacífico
América del Sur y Central
  • Brasil
  • Argentina
  • Resto de América del Sur y Central
Medio Oriente y África
  • Sudáfrica
  • Arabia Saudita
  • Emiratos Árabes Unidos
  • Resto de Medio Oriente y África
Market leaders and key company profiles
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Emotional Brain BV
  • Endoceutics, Inc.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • Sprout Pharmaceuticals, Inc.